Emtricitabine

Gilead Sciences and Aspen Pharmacare sign letter of intent to establish non-exclusive Licensing and Distribution Agreement for antiretrovirals aruvada and viread in developing world countries

Foster City, CA, and Johannesburg, South Africa, April 25, 2005 - Gilead Sciences, Inc. (Nasdaq: GILD) and JSE Securities Exchange listed Aspen Pharmacare (APN) today announced that the companies have signed a letter of intent under which they have committed to enter into a non-exclusive licensing and distribution agreement for Gilead's antiretroviral (ARV) products Truvada (emtricitabine and tenofovir disoproxil fumarate) and Viread (tenofovir disoproxil fumarate).